Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients

Schizophrenia Research

Volumn 47, Issue 1, 2001, Pages 13-25

  Theodoropoulou, St ^a   Spanakos, G ^b   Baxevanis, C N ^b   Economou, M ^c   Gritzapis, A D ^b   Papamichail, M P ^b   Stefanis, C N ^c  

^a EVANGELISMOS HOSPITAL   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

^c UNIVERSITY MENTAL HEALTH RESEARCH INSTITUTE   (Greece)

Author keywords

Antipsychotic drug; Autologous mixed lymphocyte reaction (AMLR); Cytokine; Schizophrenia; Surface marker

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE SURFACE MARKER; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS MIXED LYMPHOCYTE REACTION; CELL ACTIVATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; KILLER CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CYTOKINES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; REFERENCE VALUES; SCHIZOPHRENIA; T-LYMPHOCYTE SUBSETS;

EID: 0035863268     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(00)00007-4     Document Type: Article

References (49)

1. T-cell subsets in acute psychotic schizophrenic patients
2. Cell-mediated immunity and neurologic disease
3. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients
4. Characterisation of the anti-tumor immune response in human cancers and strategies for immunotherapy
5. Multiple sclerosis. I. Monocyte stimulatory defect in mixed lymphocyte reaction associated with clinical disease activity
6. Decreased expression of HLA-DR antigens on monocytes in patients with multiple sclerosis
7. Prothymosin-α enchances HLA-DR antigen expression on monocytes from patients with multiple sclerocis
8. Enhancement of human T lymphocyte function by prothymosin α: Increased production of interleukin-2 and expression of interleukin-2 receptors in normal peripheral blood T lymphocytes
9. Prothymosin α restores the depressed allogenic cell-mediated lympholysis and natural killer cell activity in patients with cancer
10. Differential effect of anti-β2-microglobulin on IL-2 production and IL-2 receptor expression in the primary mixed lymphocyte culture reaction
11. Abnormal immune regulation in schizophrenic patients
12. Biology of disease. Human Th1 and Th2 Cells: Functional properties, mechanisms of regulation, and role in disease
13. Interleukin-1: An immunological perspective
14. Interleukin-1α and interleukin-2 in cerebrospinal fluid of schizophrenic subjects
15. Cytokine assays: Role in evaluation of the pathogenesis of autoimmunity
16. Clinical and laboratory evidence of autoimmunity in acute schizophrenia
17. Decreased interleukin-2 production in schizophrenic patients
18. Altered interleukin-2 production in schizophrenia: Association between clinical state and autoantibody production
19. Autoimmunity in schizophrenia: A review of recent findings
20. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients
21. Abnormalities in serum concentrations of interleukin-2, interferon-α and interferon-γ in schizophrenia not detected
22. T-lymphocyte subpopulations in schizophrenic patients
23. Atypical lymphocytes in myasthenia Gravis and systemic lupus erythematosus
24. Stimulated lymphocytes in schizophrenia
25. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia
26. Insulin dependent diabetes: A disease of autoaggression
27. Lymphocyte activation and effector functions
28. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders
29. Antibodies to the human 60kDa heat-shock protein in patients with schizophrenia
30. Interleukin-2 autolerance and autoimmunity
31. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
32. Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine
33. Cytokine levels in the cerebrospinal fluid serum of patients with multiple sclerosis
34. Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status
35. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment
36. Cellular immunity in schizophrenic patients before and during neuroleptic treatment
37. Elevated levels of soluble interleukin-2 receptors in schizophrenia
38. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients
39. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers
40. Purified blood monocytes from HIV-1 infected patients produce high levels of TNF-α and IL-1
41. Changes of immunological functions after acute exacerbation in schizophrenia
42. A study of immunological state of schizophrenic patients
43. Immunological state of drug-free patients with schizophrenia
44. Immune dysfunction in schizophrenic patients
45. Cellular immune responses in systemic lupus erythematosus
46. Aberrant T cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production
47. Cortical maldevelopment, antipsychotic drugs, and schizophrenia: A search for common ground
48. Changes of plasma concentration of interleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia